NCT00737100View on ClinicalTrials.gov

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

510

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

April 30, 2010

Conditions
Cystic Fibrosis
Interventions
DRUG

Placebo Respimat

patient to receive placebo matching active drug once daily

DRUG

Tiotropium bromide 5 mcg

patient to recieve high dose tiotropium once daily

DRUG

tiotropium bromide-low dose-2.5mcg

patient to receive low dose tiotropium once daily

Trial Locations (107)

Unknown

205.339.006 Boehringer Ingelheim Investigational Site, Tucson

205.339.019 Boehringer Ingelheim Investigational Site, San Diego

205.339.023 Boehringer Ingelheim Investigational Site, Jacksonville

205.339.021 Boehringer Ingelheim Investigational Site, Miami

205.339.030 Boehringer Ingelheim Investigational Site, Orlando

205.339.031 Boehringer Ingelheim Investigational Site, Orlando

205.339.014 Boehringer Ingelheim Investigational Site, Indianapolis

205.339.022 Boehringer Ingelheim Investigational Site, Indianapolis

205.339.013 Boehringer Ingelheim Investigational Site, South Bend

205.339.001 Boehringer Ingelheim Investigational Site, Iowa City

205.339.017 Boehringer Ingelheim Investigational Site, Ann Arbor

205.339.025 Boehringer Ingelheim Investigational Site, Detroit

205.339.016 Boehringer Ingelheim Investigational Site, Grand Rapids

205.339.018 Boehringer Ingelheim Investigational Site, Lebanon

205.339.029 Boehringer Ingelheim Investigational Site, Long Branch

205.339.009 Boehringer Ingelheim Investigational Site, Morristown

205.339.002 Boehringer Ingelheim Investigational Site, Syracuse

205.339.024 Boehringer Ingelheim Investigational Site, Cleveland

205.339.020 Boehringer Ingelheim Investigational Site, Oklahoma City

205.339.032 Boehringer Ingelheim Investigational Site, Oklahoma City

205.339.010 Boehringer Ingelheim Investigational Site, Charleston

205.339.004 Boehringer Ingelheim Investigational Site, Fort Worth

205.339.005 Boehringer Ingelheim Investigational Site, Salt Lake City

205.339.026 Boehringer Ingelheim Investigational Site, Colchester

205.339.011 Boehringer Ingelheim Investigational Site, Charlottesville

205.339.003 Boehringer Ingelheim Investigational Site, Milwaukee

205.339.100 Boehringer Ingelheim Investigational Site, Westmead

205.339.101 Boehringer Ingelheim Investigational Site, Westmead

205.339.103 Boehringer Ingelheim Investigational Site, Adelaide

205.339.104 Boehringer Ingelheim Investigational Site, Subiaco

205.339.111 Boehringer Ingelheim Investigational Site, Brussels

205.339.112 Boehringer Ingelheim Investigational Site, Jette

205.339.110 Boehringer Ingelheim Investigational Site, Leuven

205.339.3310A Boehringer Ingelheim Investigational Site, Amiens

205.339.3317A Boehringer Ingelheim Investigational Site, Angers

205.339.3317C Boehringer Ingelheim Investigational Site, Angers

205.339.3317D Boehringer Ingelheim Investigational Site, Angers

205.339.3317E Boehringer Ingelheim Investigational Site, Angers

205.339.3314A Boehringer Ingelheim Investigational Site, Bron

205.339.3314B Boehringer Ingelheim Investigational Site, Bron

205.339.3314C Boehringer Ingelheim Investigational Site, Bron

205.339.3302A Boehringer Ingelheim Investigational Site, Lille

205.339.3302B Boehringer Ingelheim Investigational Site, Lille

205.339.3302C Boehringer Ingelheim Investigational Site, Lille

205.339.3303A Boehringer Ingelheim Investigational Site, Lisieux

205.339.3304A Boehringer Ingelheim Investigational Site, Montpellier

205.339.3304B Boehringer Ingelheim Investigational Site, Montpellier

205.339.3308A Boehringer Ingelheim Investigational Site, Nantes

205.339.3308B Boehringer Ingelheim Investigational Site, Nantes

205.339.3308C Boehringer Ingelheim Investigational Site, Nantes

205.339.3301B Boehringer Ingelheim Investigational Site, Paris

205.339.3312A Boehringer Ingelheim Investigational Site, Paris

205.339.3312C Boehringer Ingelheim Investigational Site, Paris

205.339.3313A Boehringer Ingelheim Investigational Site, Paris

205.339.3313B Boehringer Ingelheim Investigational Site, Paris

205.339.3318A Boehringer Ingelheim Investigational Site, Rennes

205.339.3318C Boehringer Ingelheim Investigational Site, Rennes

205.339.3318G Boehringer Ingelheim Investigational Site, Rennes

205.339.3315C Boehringer Ingelheim Investigational Site, Roscoff

205.339.3315D Boehringer Ingelheim Investigational Site, Roscoff

205.339.3306A Boehringer Ingelheim Investigational Site, Rouen

205.339.3306B Boehringer Ingelheim Investigational Site, Rouen

205.339.3307A Boehringer Ingelheim Investigational Site, Rouen

205.339.3309A Boehringer Ingelheim Investigational Site, Vandœuvre-lès-Nancy

205.339.3316A Boehringer Ingelheim Investigational Site, Vannes

205.339.49132 Boehringer Ingelheim Investigational Site, Erlangen

205.339.49137 Boehringer Ingelheim Investigational Site, Frankfurt

205.339.49133 Boehringer Ingelheim Investigational Site, Frankfurt am Main

205.339.49134 Boehringer Ingelheim Investigational Site, Freiburg im Breisgau

205.339.49131 Boehringer Ingelheim Investigational Site, Gerlingen

205.339.49145 Boehringer Ingelheim Investigational Site, Hamburg

205.339.49135 Boehringer Ingelheim Investigational Site, Hanover

205.339.49141 Boehringer Ingelheim Investigational Site, Heidelberg

205.339.49140 Boehringer Ingelheim Investigational Site, München

205.339.49142 Boehringer Ingelheim Investigational Site, München

205.339.49130 Boehringer Ingelheim Investigational Site, Tübingen

205.339.233 Boehringer Ingelheim Investigational Site, Ancona

205.339.231 Boehringer Ingelheim Investigational Site, Florence

205.339.234 Boehringer Ingelheim Investigational Site, Genova

205.339.171 Boehringer Ingelheim Investigational Site, Groesbeek

205.339.170 Boehringer Ingelheim Investigational Site, Rotterdam

205.339.105 Boehringer Ingelheim Investigational Site, Grafton / Auckland

205.339.106 Boehringer Ingelheim Investigational Site, Hamilton

205.339.221 Boehringer Ingelheim Investigational Site, Lisbon

205.339.225 Boehringer Ingelheim Investigational Site, Lisbon

205.339.223 Boehringer Ingelheim Investigational Site, Porto

205.339.224 Boehringer Ingelheim Investigational Site, Porto

205.339.07001 Boehringer Ingelheim Investigational Site, Moscow

205.339.07002 Boehringer Ingelheim Investigational Site, Moscow

205.339.07003 Boehringer Ingelheim Investigational Site, Moscow

205.339.07007 Boehringer Ingelheim Investigational Site, Rostov-on-Don

205.339.07005 Boehringer Ingelheim Investigational Site, Saint Petersburg

205.339.07006 Boehringer Ingelheim Investigational Site, Saint Petersburg

205.339.07008 Boehringer Ingelheim Investigational Site, Voronezh

205.339.07004 Boehringer Ingelheim Investigational Site, Yaroslavl

205.339.44180 Boehringer Ingelheim Investigational Site, Belfast

205.339.44190 Boehringer Ingelheim Investigational Site, Birmingham

205.339.44193 Boehringer Ingelheim Investigational Site, Boston

205.339.44192 Boehringer Ingelheim Investigational Site, Leeds

205.339.44191 Boehringer Ingelheim Investigational Site, Lincoln

205.339.44185 Boehringer Ingelheim Investigational Site, Liverpool

205.339.44186 Boehringer Ingelheim Investigational Site, Liverpool

205.339.44183 Boehringer Ingelheim Investigational Site, Nottingham

205.339.44182 Boehringer Ingelheim Investigational Site, Oxford

205.339.44194 Boehringer Ingelheim Investigational Site, Plymouth

205.339.44181 Boehringer Ingelheim Investigational Site, Sheffield

205.339.44184 Boehringer Ingelheim Investigational Site, Wolverhampton

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY